Preoperative Continuation of RAAS Inhibitors in Hypertensive Patients Undergoing Noncardiac Surgery
American Journal of Hypertension · 2026
DOI: 10.1093/ajh/hpaf171 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Sarawut Siwamogsatham und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hypertension, Renin-Angiotensin System, Postoperative Complications, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND There has been incongruent evidence on the outcomes relating to whether continuing or withholding renin-angiotensin-aldosterone system inhibitors (RAASi) preoperatively. This study aimed to systematically analyze the effect of preoperative RAASi on perioperative and postoperative outcomes in patients undergoing noncardiac surgeries. METHODS PubMed, Scopus, ScienceDirect, and Cochrane databases were used with no limitation of the starting date, till 30th September 2024. The revised Cochrane risk-of-bias tool (RoB-2) and the Newcastle-Ottawa Scale were used for quality assessment. The primary study outcomes were hemodynamic outcomes while the secondary outcomes included postoperative 30-day mortality, myocardial infarction (MI), stroke and postoperative atrial fibrillation (POAF). RESULTS Among 1897 articles, 6 eligible randomized control trials and 6 observational studies were enrolled. The patients preoperatively continuing RAASi had a higher risk of intraoperative hypotension [OR (odds ratio) = 1.54; 95% CI (confidence interval) = 1.31, 1.82], along with lower systolic and diastolic blood pressures compared to those withholding RAASi. Postoperative complications including 30-day mortality, MI, stroke, atrial fibrillation, acute kidney injury, septicemia, myocardial injury, postoperative hypertension and unplanned ICU admission, showed no significant differences. However, there was a marginal significance in lower POAF in the RAASi-continuing group (OR = 0.73, 95% CI = 0.52, 1.02). CONCLUSIONS Withholding RAASi prior to noncardiac operation significantly reduced the risk of intraoperative hypotension but may increase the chance to develop POAF without significant impact on 30-day mortality and other postoperative complications. Discontinuation of RAASi before noncardiac surgery is recommended unless obligate indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Perioperative and Ambulatory Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Integrated Specialty Medicine, St. James's Hospital, Leeds, UK.
- Pharmaceutical Care Division, School of Pharmacy, Eastern Asia University, Rangsit, Thailand.
- Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
- Revolution Health Research Consulting (RHRC) Group, Bangkok, Thailand.
ORCID-Profile: Sarawut Siwamogsatham, Su Myat Thin, Tanattha Kittisopee
Zitieren
APA
Siwamogsatham, S., Zaw, M. T., Nerapusee, O., Chongmelaxme, B., Thin, S. M., & Kittisopee, T. (2026). Preoperative Continuation of RAAS Inhibitors in Hypertensive Patients Undergoing Noncardiac Surgery. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf171
Vancouver
Siwamogsatham S, Zaw MT, Nerapusee O, Chongmelaxme B, Thin SM, Kittisopee T. Preoperative Continuation of RAAS Inhibitors in Hypertensive Patients Undergoing Noncardiac Surgery. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpaf171
BibTeX
@article{Siwamogsatham2026,
author = {Siwamogsatham, Sarawut and Zaw, Myo Thiha and Nerapusee, Osot and Chongmelaxme, Bunchai and Thin, Su Myat and Kittisopee, Tanattha},
title = {Preoperative Continuation of RAAS Inhibitors in Hypertensive Patients Undergoing Noncardiac Surgery},
journal = {American Journal of Hypertension},
year = {2026},
doi = {10.1093/ajh/hpaf171}
}
EUVIMED